Clinical Trials Now Enrolling
ABEMACICLIB IN COMBINATION WITH LY3214996 FOR RECURRENT GLIOBLASTOMA
A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma participants scheduled for resection to evaluate central nervous system (CNS) penetration
Am I eligible?
Visit ClinicalTrials.gov or use NCT identifier NCT04391595 to view inclusion criteria and additional study details.
RIBOCICLIB IN PREOPERATIVE GLIOMA
A Phase 0/2 Study of Ribociclib in Preoperative Rb-Positive Recurrent High-Grade Glioma Patients Scheduled for Resection
Am I eligible?
Visit ClinicalTrials.gov or use NCT identifier NCT02933736 to view inclusion criteria and additional study details.
RIBOCICLIB IN PREOPERATIVE MENINGIOMA PATIENTS
A Phase 0/2 Study of Ribociclib in Preoperative Rb-Positive Recurrent High-Grade Meningioma Patients Scheduled for Resection
Am I eligible?
Visit ClinicalTrials.gov or use NCT identifier NCT02933736 to view inclusion criteria and additional study details.
RIBOCICLIB AND EVEROLIMUS FOR GLIOBLASTOMA PATIENTS
A Phase 0/2 Study of Ribociclib in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection
Am I eligible?
Visit ClinicalTrials.gov or use NCT identifier NCT03834740 to view inclusion criteria and additional study details.
INFIGRATINIB FOR RECURRENT GLIOBLASTOMA
A Phase 0 study of infigratinib in recurrent high-grade glioma participants with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort
This list was last updated 05/18/2020
Get a Second Opinion>
Trial screening requests are provided at no cost and the Ivy Brain Tumor Center covers all medical costs associated with study participation outside of routine care.
Within two business days of a trial screening request, our team assesses a patient’s suitability for our clinical trials program, as well as provides additional support to the physicians managing these cases. Patients enrolled in our studies are not required to transfer their care to our center, as our philosophy is to partner with, not replace, their treatment team.
NEW DIAGNOSis?
Ivy Phase 0 clinical trials are currently available for patients whose tumors have recurred and require surgery. If you are a newly-diagnosed brain tumor patient, please feel free to contact us for additional information on current standard-of-care treatments. In the event that your tumor does recur, we will have options. Talk to an Ivy Navigator today to discuss establishing a proactive treatment plan.
